Podcasts about Reimbursement

As dental professionals, we often focus solely on dental insurance reimbursements, yet many procedures qualify for coverage under medical insurance. By understanding how to articulate the medical necessity of certain dental treatments, dentists can not only enhance patient care but also unlock additional revenue streams. Joining us is our guest Kandra Sellers. Kandra is a RDH with over 25 years in the dental industry. She is widely considered one of the most passionate and respected dental coaches. She is an educator in the field of oral systemic health, as well as founder and CEO of TIPS Medical Billing. Thanks to our episode sponsors: Septodont USA - https://www.septodontusa.com/ GC America - https://www.gc.dental/

When you're taking care of everyone else – who is taking care of you?   This week, Regina goes deep on women as caregivers and how the "sandwich generation" strain shows up financially, emotionally, and physically. Both for yourself and for loved ones, there needs to be a plan for long-term care (LTC) with clear-eyed costs, coverage myths (hello, Medicare), and policy options (traditional vs. hybrid; reimbursement vs. cash-indemnity). You'll leave with concrete next steps a new understanding of how to navigate this tricky aspect of life. Episode Highlights:   0:00 - Episode beginning 0:38 - Today's topic: caring for women caregivers 2:24 - The "sandwich generation" reality 3:07 - Burnout, time strain, mental health 4:52 - How it hits women; key stats & income impact 8:19 - What LTC means; ADLs & cognitive impairment 11:34 - Care options: adult day, home care, assisted living, hospice, nursing home 15:11 - What it costs (2023 figures) 20:18 - Paying for care: self-funding & Medicare limits 21:27 - Insurance types: traditional vs. hybrid (premiums, increases) 25:47 - Reimbursement vs. cash-indemnity—how payouts work 29:11 - When to buy, budgeting, choosing a carrier & action steps 33:32 - Outro & where to find Regina ABOUT REGINA MCCANN HESS   Regina is the author of Super Woman Wealth: How to Become Your Own Financial Hero.  As an advocate for women's financial freedom, she wrote this book to help empower women to take a bigger role in handling their money.     Regina has appeared on Schwab TV, Yahoo Finance, Forbes.com, NTD Television, CBS 3 Philadelphia, Fox 29 Philadelphia, King 5 Seattle, KTLA 5 Los Angeles and Scripps News.  She has also been quoted in numerous articles in publications such as Forbes, Business Insider, U.S. News & World Report, Yahoo Finance, USA Today, USA Wire, Word in Black, WTOP News, Mind Body Green, Money Digest, New York Post, Defender, Authority Magazine, GoBankingRates.com, Scripps and The Muse.   As Founder of Forge Wealth Management, Regina utilizes her 25+ years of financial services experience to help individuals plan, preserve and diversify their wealth.  She focuses on educating her clients while building long-term relationships with them and their families.  Her experience throughout major shifts in the markets, enables Regina to structure balanced portfolios to address specific financial goals. CONNECT WITH REGINA   Website: https://www.forgewealth.com LinkedIn: https://www.linkedin.com/in/reginamccannhess/ Facebook: https://www.facebook.com/ForgeWealth Instagram: https://www.instagram.com/forgewealthmanagement/ YouTube: https://www.youtube.com/@ForgeWealth Email: reginahess@forgewealth.com   Securities offered through LPL Financial, Member FINRA/SIPC www.finra.org, www.sipc.org Third-party posts found on this profile do not reflect the view of LPL Financial and have not been reviewed by LPL Financial as to accuracy or completeness. For a list of states in which I am registered to do business, please visit www.forgewealth.com. This material was prepared by Brighthouse Financial. Brighthouse Financial is not affiliated with, nor endorsed by, LPL Financial, Private Advisor Group or Forge Wealth Management.

This panel was recorded September 18, 2025.⁠⁠⁠⁠ We hope you'll join us live in the future to ask your own questions and participate in the attendee chat! See similar events on demand and read other free MedTech resources at ⁠RQMplus.com⁠.Manufacturers often focus on MDR or IVDR and miss cross-cutting EU laws that impact CE marking, technical documentation, quality systems, and reporting. As a result, devices may be delayed, blocked from the market, or recalled, and manufacturers may suffer legal penalties and reputational harm.In this RQM+ Live! panel discussion, experts from BSI, Brabners, and RQM+ map how sectoral, horizontal, and national requirements fit together, how notified bodies assess them, and how to build an evidence-based path to EU market access.We cover practical implications of recent and emerging regulations, including:Batteries Regulation (EU) 2023/1542AI Act (EU) 2024/1689Packaging and Packaging Waste Regulation (EU) 2025/40European Health Data Space Regulation (EU) 2025/327You'll learn:About the market surveillance regulation (EU) 2019/1020 and EU Blue Guide.How to identify all applicable legislation for your product and verify coverage.What notified bodies expect to see and the typical level of scrutiny.How to structure your compliance register, QMS updates, and regulatory reporting.Transition timelines and planning tactics to avoid last-minute surprises.Who should listen: Regulatory, quality, clinical, legal, and product leaders responsible for EU market access for medical devices and IVDs.Panelists and moderator:Greg Griffin, PhD, MRSE – Technical Specialist, BSIClaire Burrows – Regulatory Partner, BrabnersChris Parr, PMP – Principal, RQM+Jaishankar Kutty, PhD – Vice President of Regulatory Affairs, Reimbursement, & Market Access, RQM+ (Moderator)--

Dr. Jeanette Benigas, SLP, sits down with Oregon SLP Kara Hayden, MS/SLP, to unpack how clinicians organized, lobbied, and helped pass a state law requiring hourly pay, ending pay-per-visit in home health and hospice. They cover timelines, productivity pressure, joining an existing nurses' union, building a small core team, securing a sponsor, writing testimony, and answering the big question: “Won't agencies just pay less?” If you're ready to push for change in your state, pay models, Medicaid rules, or workplace policies, this episode gives you the blueprint and the courage to start.Brought to you by Verse Therapy, the business-in-a-box solution for SLPs who want to start, run, and grow private practice with confidence. Verse Therapy makes private practice a realistic option by providing an AI-integrated EHR, marketing support, cohort trainings, and a team that helps you build your brand and run your practice like a pro. Learn more at versetherapy.com.Stop paying to track ASHA-approved CEUs. Save your money and set up for a FREE CEU/PDH tracker with Speech Therapy PD. While you are there, get $10 off a professional subscription with the code FixSLP10!

This Episode Aired Previously. For information anytime, please call 1-855-821-5900 or visit pocketemploymentlawyer.ca

In this episode of Medsider Radio, we sat down with Tim Gleeson, CEO of BRIJ Medical, a company rethinking one of the oldest procedures in medicine — surgical wound closure.BRIJ's Brijjit Force Modulating Tissue Bridge is a small, non-invasive clip designed to redistribute tension across incisions, helping wounds heal with fewer complications and smaller scars.An accomplished entrepreneur and investor, Tim also founded and led Novasyte Health through its acquisition by IQVIA and later launched VIDANT Capital. A former Medtronic executive, Tim brings global experience and a lifelong passion for building impactful medtech ventures.In this interview, Tim shares why the biggest opportunities often hide in “boring” markets, how focusing on physician champions and patient psychology drives commercial traction, and why the best fundraisers plan for twice the time and four times the cost.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Gleeson.

Send us a textTwo sentences from PDAC can potentially change the course of manufacturing history for O & P: additive manufacturing is now explicitly acceptable for coding prosthetic devices that meet existing HCPCS descriptions. We unpack what that clarity means for clinicians, patients, vendors, and payers, and how to adopt 3D printing.• Why PDAC's language ends the gray area for 3D‑printed prosthetics• What PDAC and DME MAC do and how they shape coding• How to match additive devices to existing L code descriptions• Documentation discipline to avoid denials and audits• FDA's proactive stance and signals to industry• Medicare vs Medicare Advantage realities for reimbursement• When new codes help vs when they stall at zero pay• Scaling care amid workforce shortages using digital workflows• Using additive to improve fit, speed, and repeatability• Practical steps to start: scanning, CAD, materials, recordsSpecial thanks to Advanced 3D for sponsoring this episode.Support the show

Send us a text

Today on The McCarthy Report, Andy and Rich discuss Trump's DOJ reimbursement request, the Bolton indictment, and much more. This podcast was edited and produced by Sarah Colleen Schutte. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Medsider Radio, we sat down with Kate Dilligan, CEO of Cooler Heads.Cooler Heads is a commercial-stage company addressing a problem affecting many chemotherapy patients undergoing treatment for solid tumors: hair loss and the loss of privacy that comes with it. The company's FDA-cleared medical device, Amma, makes scalp cooling accessible by fitting into infusion center workflows rather than disrupting them.Kate brings an unconventional background to medtech — from political fundraising to developing classified software for the U.S. government. As a solo female founder who had never worked in hardware, she started Cooler Heads in 2018 after her own experience with breast cancer. By mid-2025, the company had raised $11 million in Series A funding and placed devices across 27 states, with most accounts having never offered scalp cooling before.In this interview, Kate shares how to design for health system adoption by solving workflow problems first, why saying “no” to scope creep protects your first-generation product, and how political fundraising tactics translate directly to building investor relationships in medtech.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Kate Dilligan.

Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs.  ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care. Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line." "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer." #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations archehealth.ai Download the transcript here

Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs.  ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care. Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line." "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer." #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations archehealth.ai Listen to the podcast here

Lumos Diagnostics Senior Vice President Paul Kase joined Steve Darling from Proactive to discuss a major milestone for the company — the signing of an agreement with WellStreet Urgent Care to accelerate testing and reimbursement pathways for its FebriDx® rapid host-response test. The initiative will be launched through WellStreet's joint venture with Piedmont Urgent Care in Atlanta, Georgia, marking a key step toward broader US adoption. Under the program, FebriDx will be deployed at a Piedmont Urgent Care site handling approximately 50 respiratory-infection patients per day, providing Lumos with high-quality operational data on workflow efficiency, patient outcomes, and payer engagement. Kase explained that WellStreet will procure FebriDx through PHASE Scientific and submit reimbursement claims for each test, while Pro-spectus will oversee billing data management and claims analysis. This collaborative approach is designed to generate real-world evidence to support the development of comprehensive reimbursement and coverage policies with major U.S. insurers. Pending the granting of a CLIA waiver for FebriDx, Lumos and WellStreet plan to expand the program nationwide, leveraging insights from the pilot to guide a potential rollout across more than 140 WellStreet urgent care locations across the United States. Kase added, “This partnership represents a major step in bringing FebriDx to scale in the U.S. healthcare system. By validating operational efficiency and demonstrating reimbursement viability, we're building the foundation for widespread clinical adoption of a test that helps physicians quickly differentiate between bacterial and viral infections.” #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #LumosDiagnostics #FebriDx #PointOfCareTesting #HealthcareInnovation #UrgentCare #DiagnosticTesting #InfectionDetection #AntibioticStewardship #MedicalTechnology #ProactiveInvestors

Published October 16, 2025 In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.ResourcesFind past “Answers From the Lab” podcasts on LDTs and PAMA

In this episode of Medsider Radio, we sat down with Young Juhn, CEO of Wellysis.Wellysis is the Samsung spinout behind S-Patch, a lightweight wearable that enables long-term ECG monitoring without the discomfort of established cardiac monitoring devices.Young has spent more than two decades bridging hospital and home-based care — from his early career at Johnson & Johnson, to more than a decade at Kaiser Permanente, to leading healthcare innovation at Samsung before spinning out Wellysis in 2019.In this interview, Young shares why patient interviews should shape product design, how regulatory clearance is just the starting point for global commercialization, and why building a medical foundation before branching into consumer markets is critical for lasting adoption.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Young Juhn.

Hot on the heels of CUTISS' $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company's mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.

Welcome to the ABA Business Leaders News, the go-to show for aspiring and current ABA practice owners who want to keep up to date with the latest happenings in the world of ABA. Every week, your hosts April and Stephen Smith bring you actionable insights, news, and real-world advice to help you navigate the challenges and celebrate the wins of starting and running your own ABA practice.

This episode tackles the often-overlooked but critical topic of medical device reimbursement. Host Etienne Nichols speaks with Haley King, co-founder and CEO of Paxos Health, about why this process is just as vital as FDA approval for a device's commercial success. They explore the journey a medical device takes, highlighting the distinction between FDA approval and securing reimbursement from payers.Haley explains the three key pillars of reimbursement: coding, coverage, and payment. She delves into the complexities of CPT codes and the significant difference between a temporary Category 3 code and the gold-standard Category 1. The discussion also covers the immense challenges medical device companies face, including the lengthy timeline—sometimes years—to secure payer coverage, which can be a make-or-break factor for startups. The conversation wraps up with a look at how artificial intelligence is beginning to streamline the cumbersome, manual process of patient access and appeals.Key Timestamps1:45 - The initial challenge of making coverage match medical need.3:30 - The three-part reimbursement pathway: coding, coverage, and payment.5:50 - Navigating CPT codes and the difference between Category 1 and Category 3.10:15 - Common challenges for medical device companies seeking payer coverage.13:20 - The multi-year timeline to achieve Medicare coverage for innovative devices.15:00 - Advice for regulatory and quality professionals on speeding up reimbursement.20:10 - How AI is currently being used in patient access and reimbursement.24:45 - Debating the accuracy of AI and its role in replacing human expertise.Quotes"A lot of times patients are not going to be able to pay out of pocket for expensive medical treatments, and a lot of times providers are not going to be able to write off those treatments on their side. So somebody needs to pay for this. And that's usually the health insurance companies..." — Haley King"I think that for this sort of a use case [AI], you're always going to want some human in the loop... AI has the potential to be super, super powerful in this space, but I think you're always going to want to have human experts involved." — Haley KingTakeawaysIntegrate reimbursement strategy early: Unlike FDA approval, which focuses on safety and efficacy, payers also demand evidence of a device's clinical and economic value. Medical device companies, particularly startups, should integrate reimbursement planning into their pitch decks and product development timelines from the outset.Recognize the two-step process: FDA approval is not a golden ticket to reimbursement. Companies must understand the subsequent and often lengthy process of securing coding, coverage, and payment from payers like CMS and private insurance companies, which can take several years.Enhance clinical trials for payers: Regulatory and quality professionals can speed up the reimbursement process by designing clinical trials that not only meet FDA requirements but also generate robust data to prove a device's clinical and economic value. This may involve including additional endpoints to justify the cost.Harness AI for efficiency, not replacement: AI is a powerful tool for automating the tedious parts of reimbursement, such as sifting through patient records and payer policies. However, it should be viewed as a way to enhance, not replace, the work of human experts who can handle complex edge cases and appeals.Be aware of coding complexities: The distinction...

TOP STORIES - Florida secures FEMA reimbursement for state-run detention facilities, including the controversial Alligator Alcatraz. Governor Ron DeSantis signals a property tax reform proposal and hints at a special session. A Royal Caribbean cruise ship returns to Miami after a norovirus outbreak, while Miami-Dade unveils a driverless police car. Plus, activists protest ICE involvement at the 2026 FIFA World Cup, and Floridians weigh in on rising grocery costs.

TOP STORIES - Florida secures FEMA reimbursement for state-run detention facilities, including the controversial Alligator Alcatraz. Governor Ron DeSantis signals a property tax reform proposal and hints at a special session. A Royal Caribbean cruise ship returns to Miami after a norovirus outbreak, while Miami-Dade unveils a driverless police car. Plus, activists protest ICE involvement at the 2026 FIFA World Cup, and Floridians weigh in on rising grocery costs.See omnystudio.com/listener for privacy information.

When it is okay to ask for a reimbursement for using your own equipment in the field? Today the hosts discuss the complexities of getting reimbursed for using your own vehicle, getting food allowance, and what the company is required to provide. We will also talk about the difficulties of navigating university reimbursement processes that comes with running an archaeological field school.LinksThis video shows what it's like to wait for a reimbursement from a university: Moving Through TimeTranscriptsFor rough transcripts of this episode go to https://www.archpodnet.com/crmarchpodcast/319Blogs and Resources:Bill White: Succinct ResearchDoug Rocks-MacQueen: Doug's ArchaeologyChris Webster: DIGTECH LLCAndrew KinkellaKinkella Teaches Archaeology (Youtube)Blog: Kinkella Teaches ArchaeologyArchPodNetAPN Website: https://www.archpodnet.comAPN on Facebook: https://www.facebook.com/archpodnetAPN on Twitter: https://www.twitter.com/archpodnetAPN on Instagram: https://www.instagram.com/archpodnetAPN ShopAffiliatesMotion Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When it is okay to ask for a reimbursement for using your own equipment in the field? Today the hosts discuss the complexities of getting reimbursed for using your own vehicle, getting food allowance, and what the company is required to provide. We will also talk about the difficulties of navigating university reimbursement processes that comes with running an archaeological field school.LinksThis video shows what it's like to wait for a reimbursement from a university: Moving Through TimeTranscriptsFor rough transcripts of this episode go to https://www.archpodnet.com/crmarchpodcast/319Blogs and Resources:Bill White: Succinct ResearchDoug Rocks-MacQueen: Doug's ArchaeologyChris Webster: DIGTECH LLCAndrew KinkellaKinkella Teaches Archaeology (Youtube)Blog: Kinkella Teaches ArchaeologyArchPodNetAPN Website: https://www.archpodnet.comAPN on Facebook: https://www.facebook.com/archpodnetAPN on Twitter: https://www.twitter.com/archpodnetAPN on Instagram: https://www.instagram.com/archpodnetAPN ShopAffiliatesMotion Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Medsider Radio, we sat down with Josh Vose, CEO of Tulavi Therapeutics.Tulavi is advancing hydrogel-based implants like the allay Hydrogel Cap, which is designed to optimize nerve injury recovery and reduce the risk of neuroma formation.Josh is a physician, engineer, and entrepreneur with more than 20 years of experience in medical devices. He has held leadership roles at Medtronic following its acquisition of PEAK Surgical and drove growth at startups including SIA Health, which he led through commercialization and acquisition by Integra LifeSciences.In this interview, Josh shares why defining the clinical problem with absolute clarity is the foundation of medtech success, and how leaning into the harder regulatory path can create lasting moats.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Josh Vose.

Accessing enteral nutrition (EN) through durable medical equipment (DME) providers often hinges on one critical factor: medical necessity. Yet payer requirements, documentation standards, and coverage rules can make the process complicated for both clinicians and patients.In this episode, host Christina Rollins sits down with Kim Iles and Brittany Buchholz to unpack how DME suppliers determine coverage, clarify what constitutes medical necessity, and explore how policies differ across Medicare, Medicaid, and commercial insurance.

In this episode, after an Ask the Editor question about censorship goes existential, Mike and Sarah discuss a plot twist in the six-town school regionalization saga and revisit an EBT theft story that began in May. Plus: melons, blue comics, pessimism frosting, newspaper-themed weddings, and poetic indices. Intrigued? Confused? Listen to find out!Subscribe to the Montague Reporter newspaper at https://montaguereporter.org/subscribe/ 

In this episode of Medsider Radio, we sat down with Ahmed Elmouelhi, CEO of TRiCares.  TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men's health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Ahmed Elmouelhi.

Pharmacy Benefit Managers.  Reimbursements not covering cost of drugs.  Wegovy/Zepbound prices fall but access is still limited.  Bill 242 Medicare Supplements coverage and open enrollment period will doom lower prices.

UCR 259: Bladder Cancer Reimbursement Strategies – Using Unlisted J Codes and the New Zusduri Hub ToolsSeptember 19, 2025 In this episode, Scott, Mark, and Ray Painter dive into bladder cancer reimbursement with a special focus on billing strategies for new intravesical therapies like Zusduri, which currently lack established J codes. Mark outlines the complete reimbursement pathway from diagnosis coding through installation documentation, prior authorizations, appeals, and follow-up. They discuss the importance of accurate diagnosis flow, clear drug documentation, and the nuances of billing unlisted codes—including Box 19 tips and JW modifiers.The episode also introduces PRS Network's new Zusduri Reimbursement Hub, including a custom J Code calculator designed to help practices manage invoicing timelines, track payment cycles, and streamline claim submissions. This tool is a game-changer for practices adopting new therapies. The Painters wrap up with reflections on the importance of payer education, the role of pioneers in improving access to innovative urology treatments, and how this supports better outcomes for patients.Urology Advanced Coding and Reimbursement SeminarInformation and RegistrationPRS Coding and Reimbursement HubAccess the HubFree Kidney Stone Coding CalculatorDownload NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and AdminsPRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a Quote Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

In this episode of Medsider Radio, we sat down with Marc Penna, CEO of Voyager Biomedical. Voyager is a clinical-stage company tackling one of the most persistent challenges in dialysis care: reliable vascular access. Marc has more than 20 years of experience leading clinical research and regulatory programs across cardiology, vascular disease, and oncology. Since 2014, he has focused on early-stage ventures, with leadership roles at Intact Vascular and Vesper Medical — both acquired by Philips — as well as senior positions at Edwards Lifesciences, Boston Scientific, and AngioDynamics.In this interview, Marc shares how to pressure-test new medtech ideas, why collaboration with regulators and trial sites builds lasting credibility, and how disciplined fundraising and smart exit planning can set startups apart.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Marc Penna.

A split or shared visit is an evaluation and management (E/M) service performed jointly by a physician and a non-physician practitioner (NPP) from the same group in a facility setting. Under applicable laws and regulations, either the physician or the NPP may bill for the service—provided they deliver it independently. Reimbursement goes to the practitioner […] The post Split/Shared Visits Update appeared first on Terry Fletcher Consulting, Inc..

The Myths of Biotech Investing Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. Biotech investing differs from tech investing. There's often no revenue traction to assess. The startup must navigate the FDA path while dealing with cutting-edge devices and therapeutics. Here are some myths of biotech investing: Myth 1-Biotech startups are building companies. In many cases, the biotech startup will sell during the clinical trials or at FDA approval. They rarely proceed to launching a business. Myth 2- Biotechs take much longer than tech companies to exit. Most biotech startups exit in the 3 to 5 year range, which is often shorter than tech companies. Myth 3- Regulatory is the key hurdle to overcome. In reality, it's proving the therapeutic works. Most drugs fail in clinical trials and never reach FDA submission. Myth 4-Reimbursement is the key to a successful biotech therapy. In reality, it's showing value to the physician and patient through high efficacy and low toxicity, which is the key to success. Consider these myths in analyzing biotech startups for investment.   Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

Jim and Chris discuss listener questions on surviving spouse Social Security benefits and Roth conversions, SSDI and pensions, the Social Security Fairness Act, managing large HSA reimbursements, and choosing between MYGAs and the TSP G Fund.(7:45) George asks whether Roth conversions count toward the earnings test when planning to claim his surviving spouse Social Security […] The post Social Security, HSA Reimbursements, and MYGAs: Q&A #2536 appeared first on The Retirement and IRA Show.

It's been nearly a year since the launch of the Indy Health District - an initiative that hopes to change those statistics. Indiana lawmakers this year tasked the Secretary of State's office with studying whether to require all counties to use vote centers. The Indiana Family and Social Services Administration is cutting voucher reimbursement rates for the Child Care and Development Fund. As the climate warms, armadillos are moving north — forcing communities to adjust to the unexpected newcomer. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

What happens when politics ignores kids? Pediatrician and South Carolina Senate hopeful Dr. Annie Andrews joins me to talk about why children's health depends on more than just doctor's visits - it depends on the policies shaping their lives. From Medicaid cuts to paid leave, gun safety, and the cost of insulin, Dr. Andrews explains why neutrality in medicine isn't an option and why pediatricians, and parents, have a responsibility to speak up. We discuss: Why Dr. Andrews made the leap from pediatrics to politics How policies like Medicaid cuts directly hurt children, families, and the health care system Why pediatricians and parents need to get louder in advocacy How healthcare has become political and why we need to be louder for our kids' future  The child tax credit and other policies that could transform children's futures How better policy can prevent burnout among doctors and improve care for every family To connect with Dr. Annie Andrews follow her on Instagram @annieandrewsmd, check out all her resources at https://drannieandrews.com/ We'd like to know who is listening! Please fill out our Listener Survey to help us improve the show and learn about you! 00:00 – Why Advocacy Alone Isn't Enough 01:11 – Politics Is Already in Our Lane 02:32 – Meet Dr. Annie Andrews: Pediatrician, Mom, Senate Hopeful 04:04 – From Clinic to Campaign: Why She Ran 07:06 – Kids Left Behind in Red vs. Blue States 09:30 – Why Staying Neutral Can Hurt Kids 12:22 – Advocacy vs. Politics: What Really Creates Change 15:26 – Looking Ahead: Policy Priorities if Elected 16:50 – Medicaid Cuts and What They Mean for Families 22:02 – How Cuts Affect Doctors, Patients, and the Whole System 25:14 – Burnout, Reimbursement, and a Broken System 28:15 – Why Pediatricians Must Step Into Politics 30:17 – Fixing the Workforce Crisis in Pediatrics 33:52 – Final Call to Action: Getting Loud for Kids 35:30 – How to Connect With Dr. Annie Andrews 38:21 – Closing Thoughts: Hope Through Action Our podcasts are also now on YouTube. If you prefer a video podcast with closed captioning, check us out there and ⁠subscribe to PedsDocTalk⁠. Get trusted pediatric advice, relatable parenting insights, and evidence-based tips delivered straight to your inbox—join thousands of parents who rely on the PDT newsletter to stay informed, supported, and confident. ⁠⁠⁠⁠Join the newsletter⁠⁠⁠⁠! And don't forget to follow ⁠⁠⁠⁠@pedsdoctalkpodcast⁠⁠⁠⁠ on Instagram—our new space just for parents looking for real talk and real support. We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on the ⁠PedsDocTalk Podcast Sponsorships⁠ page of the website.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Margins are razor-thin on Amazon.Reimbursements are one of the easiest places to lose money. In this live session, Neil Twa and Lisa from GETIDA break down what reimbursements are, why they matter, and the major Amazon policy changes every seller needs to know.They cover how lost and damaged inventory impacts your bottom line, why new claim deadlines are shrinking from 18 months down to as little as 60 days, and how sellers can recover thousands in “found money” by auditing their accounts.In This Episode, We Cover:✅ The new Amazon rules cutting claim timelines from 18 months to 60 days✅ Why ignoring reimbursements is like handing free money to Amazon✅ Case studies: sellers recovering $40,000+ in reimbursements 

In this episode of Medsider Radio, we sat down with Christopher Haig, co-founder and CEO of Efemoral Medical. Efemoral is developing bioresorbable scaffold technology for peripheral arterial disease. Chris has over 25 years of experience in cardiovascular devices, holding leadership roles at strategics including Guidant Corporation and Abbott Vascular, and driving growth at startups such as Calypso Medical and QT Vascular, where he built commercial infrastructure and launched multiple products ahead of its $55 million IPO.In this interview, Chris shares how bioresorbable scaffold technology found new life for peripheral arterial disease — and the lessons on matching tech to significant needs and choosing trial sites for lasting data.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Christopher Haig.

What happens when politics ignores kids? Pediatrician and South Carolina Senate hopeful Dr. Annie Andrews joins me to talk about why children's health depends on more than just doctor's visits - it depends on the policies shaping their lives. From Medicaid cuts to paid leave, gun safety, and the cost of insulin, Dr. Andrews explains why neutrality in medicine isn't an option and why pediatricians, and parents, have a responsibility to speak up. We discuss: Why Dr. Andrews made the leap from pediatrics to politics How policies like Medicaid cuts directly hurt children, families, and the health care system Why pediatricians and parents need to get louder in advocacy How healthcare has become political and why we need to be louder for our kids' future  The child tax credit and other policies that could transform children's futures How better policy can prevent burnout among doctors and improve care for every family To connect with Dr. Annie Andrews follow her on Instagram @annieandrewsmd, check out all her resources at https://drannieandrews.com/ We'd like to know who is listening! Please fill out our Listener Survey to help us improve the show and learn about you! 00:00 – Why Advocacy Alone Isn't Enough 01:11 – Politics Is Already in Our Lane 02:32 – Meet Dr. Annie Andrews: Pediatrician, Mom, Senate Hopeful 04:04 – From Clinic to Campaign: Why She Ran 07:06 – Kids Left Behind in Red vs. Blue States 09:30 – Why Staying Neutral Can Hurt Kids 12:22 – Advocacy vs. Politics: What Really Creates Change 15:26 – Looking Ahead: Policy Priorities if Elected 16:50 – Medicaid Cuts and What They Mean for Families 22:02 – How Cuts Affect Doctors, Patients, and the Whole System 25:14 – Burnout, Reimbursement, and a Broken System 28:15 – Why Pediatricians Must Step Into Politics 30:17 – Fixing the Workforce Crisis in Pediatrics 33:52 – Final Call to Action: Getting Loud for Kids 35:30 – How to Connect With Dr. Annie Andrews 38:21 – Closing Thoughts: Hope Through Action Our podcasts are also now on YouTube. If you prefer a video podcast with closed captioning, check us out there and ⁠subscribe to PedsDocTalk⁠. Get trusted pediatric advice, relatable parenting insights, and evidence-based tips delivered straight to your inbox—join thousands of parents who rely on the PDT newsletter to stay informed, supported, and confident. ⁠⁠⁠⁠Join the newsletter⁠⁠⁠⁠! And don't forget to follow ⁠⁠⁠⁠@pedsdoctalkpodcast⁠⁠⁠⁠ on Instagram—our new space just for parents looking for real talk and real support. We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on the ⁠PedsDocTalk Podcast Sponsorships⁠ page of the website.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Telehealth for speech therapy is under threat, and if Medicare pulls access, the consequences could ripple far beyond one program. Adults, families, and care partners lose critical care options, but that's just the start. A Medicare rollback could trigger private insurance and Medicaid to follow suit, resulting in reduced access across the board. In this episode, we explore why telehealth is crucial for patients who can't drive, for care partners balancing demanding schedules, and for clinicians serving rural and underserved communities. You'll also get advocacy tools, ready-to-use letter templates, and simple ways to mobilize your practice and patients to keep telehealth accessible.Find all of the advocacy tools you need here to participate in the telehealth call to action, or check out Katie's SLPs Blueprint to Medicare Success and get $100 off with the code FixSLP.Stop paying to track ASHA-approved CEUs. Save your money and set up for a FREE CEU/PDH tracker with Speech Therapy PD. While you are there, get $10 off a professional subscription with the code FixSLP10! Thank you to our sponsor, ⭐️ Befitting You Medical Supply ⭐️,  offering AAC devices with hands-on assessments, education, and support for patients and families. Check them out!New here? Subscribe, share with a colleague, and call the Minivan Meltdown line at fixslp.com to add your voice.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Senior Editor Sue Sutter discuss the impact of US Food and Drug Administration's COVID-19 vaccine indication changes and recission of the associated emergency use authorizations, as well as the postmarketing studies that now are required (:40), and their potential impact on access and reimbursement (12:20). More On These Topics From The Pink Sheet COVID-19 Vaccines: Pfizer Arguments To Keep EUA Failed To Persuade US FDA's Prasad: https://insights.citeline.com/pink-sheet/vaccines/covid-19-vaccines-pfizer-arguments-to-keep-eua-failed-to-persuade-us-fdas-prasad-V3X2OEBZE5HRHKO7KMMCFXBM2Q/ US FDA Updates COVID-19 Vaccine Formulations, Revokes EUAs, ACIP Use Decision Next: https://insights.citeline.com/pink-sheet/vaccines/us-fda-updates-covid-19-vaccine-formulations-revokes-euas-acip-use-decision-next-VBXJDSOA6BCOXNCA2TAH27EBJY/ A US FDA Move to Revoke Pfizer's Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions: https://insights.citeline.com/pink-sheet/vaccines/a-us-fda-move-to-revoke-pfizers-pediatric-covid-19-vaccine-eua-could-raise-supply-questions-ZX26DBENHFCOHPBGMPFPQB6REQ/ Changes In Pediatric COVID-19 Vaccine Recommendations Causing Coverage Confusion: https://insights.citeline.com/pink-sheet/vaccines/changes-in-pediatric-covid-19-vaccine-recommendations-causing-coverage-confusion-WDEYUVJXGBCGBEVBQ2I6INH554/

In this episode of Medsider Radio, we sat down with Howard Rosen, co-Founder and CEO of Evident Vascular, a company developing an AI-powered intravascular ultrasound (IVUS) platform to improve vascular imaging and intervention. Before co-founding Evident, Howard held senior leadership roles at Intact Vascular and Vesper Medical, guiding both companies through successful acquisitions by Philips. He also served in executive roles at Haemonetics and BG Medicine, and spent over two decades at Boston Scientific, where he held a range of leadership positions across the peripheral and cardiovascular franchises.In this interview, Howard shares why launching right — not fast — is the key to success in medtech. He breaks down how Evident built early momentum by investing in deep market validation, engaging KOLs as true collaborators, and resisting scope creep at every turn. Howard also unpacks the company's deliberate regulatory strategy, using early FDA engagement as a tool to de-risk development. On the fundraising front, he explains why board composition matters more than valuation, and why strategic acquirers respond best to credibility, not cold outreach.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Howard Rosen.

For the latest and most important news of the day | https://www.thecanadianpressnews.ca To watch daily news videos, follow us on YouTube | https://www.youtube.com/@CdnPress The Canadian Press on X (formerly Twitter) | https://twitter.com/CdnPressNews The Canadian Press on LinkedIn | https://linkedin.com/showcase/98791543

For the latest and most important news of the day | https://www.thecanadianpressnews.ca To watch daily news videos, follow us on YouTube | https://www.youtube.com/@CdnPress The Canadian Press on X (formerly Twitter) | https://twitter.com/CdnPressNews The Canadian Press on LinkedIn | https://linkedin.com/showcase/98791543

https://dianacantureyna.substack.com/podcast https://www.cultivatingself.org/reclaiminghealthcarefellowship Our guest, Jayda Greco, is a partner at McDermott Will & Schulte, where she focuses on the intersection of healthcare and law. With a deep background in digital health, she's an expert in navigating the complex regulatory landscape, including privacy, compliance, and reimbursement. https://www.mwe.com/insights/food-as-medicine-a-deep-dive-into-reimbursement/ https://academic.oup.com/healthaffairsscholar/article/2/2/qxae013/7595880  

In this episode, Rodney Adams, SVP of Finance & Reimbursement for the Tennessee Hospital Association, discusses the intersection of healthcare finance.

In this episode of Medsider Radio, we sat down withTracy MacNeal, President and CEO of Materna Medical. Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and Milli, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women's health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women's Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tracy MacNeal.

Southwest Michigan's Afternoon News podcast is prepared and delivered by the WSJM Newsroom. For these stories and more, visit https://www.wsjm.com and follow us for updates on Facebook. See omnystudio.com/listener for privacy information.

It's YOUR time to #EdUpStay ahead of the conversation in higher ed. Get early, ad-free access & exclusive leadership content by supporting Elvin & Joe for only $5.99 a month. YOU can also donate or gift a subscription at edupexperience.comIn this episode, YOUR guest is Robert Towner, Associate Vice President, EDGE - Northeastern UniversityYOUR host is ⁠⁠Dr. Joe Sallustio  How does Northeastern's Edge unit break away from traditional academic silos to create interdisciplinary programs? What makes performance based admissions a game changer for corporate partnerships in higher ed? How is Edge transforming tuition reimbursement from uncontrolled spending into strategic talent management? Topics include:B2B talent management partnerships vs traditional articulation agreements Stackable credentials & digital upskilling hubs Prior learning assessment for working professionals Listen in to #EdUpThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr. Joe Sallustio⁠⁠⁠⁠● Join YOUR EdUp community at The EdUp ExperienceWe make education YOUR business!P.S. Support the podcast trusted by higher ed leaders. Get early, ad-free access & exclusive leadership content by supporting Elvin & Joe for only $5.99 a month. YOU can also donate or gift a subscription at edupexperience.com

In this episode of Medsider Radio, we sat down with Joanna Nathan, CEO and co-founder of Prana Surgical — a startup developing image-guided surgical platforms for precision oncology.  Joanna's career spans translational research at Texas Heart Institute, product development at Saranas, and portfolio management at Mercury Fund and Johnson & Johnson's Center for Device Innovation. She mentors founders through her not-for-profit organization Enventure and teaches entrepreneurship at Rice University's Jones School of Business.In this interview, Joanna shares her framework for evaluating which medtech ideas merit pursuit, revealing three critical signals every founder should look for: clinical urgency that requires no convincing, favorable asymmetry between value and technical risk, and optimal market timing. Joanna also demonstrates how systematic grant applications and strategic resource allocation can extend runway while building investor credibility, and addresses the unique psychological challenges of building life-critical devices.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Joanna Nathan.

An interview with Dr. Kathryn Schmitz, Interim Director of the UPMC Hillman Cancer Center.We have one randomized control trial showing, in one group of cancer patients, that there is a disease free survival benefit and a mortality benefit, and we know that there's a lot of nice to have outcomes, right? Nice, nice to have is quality of life, things that are not going to be something that the payer pays for. So there's our challenge, that's the truth, that's the truth of our situation. That's why it's going to be difficult. And I think the challenge provides us one of the first opportunities to be able to really lay all of that bare. And then the question becomes, how do we motivate hospitals, healthcare systems and payers to pay for something when there is no profit in it for them?Dr. Kathryn SchmitzEvidence for exercise as a standard of care in cancer treatmentImproving access to exercise oncology programsMaking the case for reimbursement for exercise oncology programsCMS coverage of supervised exercise training for people with cancerMoving Through Cancer areas of focusPrognosis for 2029https://www.movetolivemore.com/https://www.movetolivemore.com/bookhttps://www.linkedin.com/company/move-to-live-more@MovetoLiveMore